Seattle Genetics is an emerging global multi-product biotechnology company that develops and commercializes innovative antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. In addition to one marketed product, we are advancing a deep product pipeline designed to address significant unmet medical needs.

**ADCETRIS: Broad Global Development Plan**

Our lead program, ADCETRIS® (brentuximab vedotin) is the first in a new class of ADCs and, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available in more than 65 countries. To further expand the ADCETRIS opportunity, we are conducting a broad clinical development program evaluating its potential to become the foundation of treatment for CD30-expressing lymphomas, including Hodgkin lymphoma, cutaneous T-cell lymphoma and mature T-cell lymphomas. Across both corporate and investigator trials, ADCETRIS is in more than 70 clinical trials, including more than 50 in Hodgkin lymphoma.

**Vadastuximab Talirine: Pivotal Phase 3 Program**

We also are advancing vadastuximab talirine (SGN-CD33A; 33A), a novel ADC that is being evaluated in the pivotal phase 3 CASCADE trial for acute myeloid leukemia (AML). AML is a significant unmet need, as treatments have not meaningfully changed in more than four decades. 33A is targeted to CD33 which is expressed on most AML cells as well as in myelodysplastic syndrome (MDS), often a precursor to AML.

**ADCs: Integral Part of Cancer Therapy**

ADCETRIS and vadastuximab talirine are two of more than 20 ADCs in clinical development using our proprietary technology. We are also advancing enfortumab vedotin (ASG-22ME) for urothelial cancer under our collaboration with Astellas, and SGN-LIV1A for triple-negative breast cancer, as well as several other internal clinical and preclinical programs. Our deep product pipeline provides opportunities across hematologic malignancies and solid tumors.

Our ADC technology is also employed by collaborators who are advancing multiple programs using Seattle Genetics’ proprietary approach to empowering antibodies. Through internal research and development, collaborations and scientific innovation, we are committed to improving treatment outcomes for patients.
**Empowering Antibodies, Targeting Cancer**

Antibody-drug conjugates (ADCs) have the potential to become an integral part of cancer treatment. ADCs harness the targeting ability of monoclonal antibodies to deliver potent cell-killing (cytotoxic) agents directly to cancer cells.

The key components of our proprietary ADC technology are the potent synthetic cytotoxic agents and the stable linkers that attach the cytotoxic agent to an antibody. The antibody is targeted against a specific tumor-associated receptor on cancer cell surfaces. Our linker systems release the cell-killing agent once inside the targeted cells. This approach is intended to spare non-targeted cells and reduce the toxic effects of traditional chemotherapy while enhancing antitumor activity.

We are conducting significant research activities to continue advancing our ADC technology and are committed to staying the leader in ADC development.

**Auristatins**

The lead group of cytotoxic agents that we have developed is a class of microtubule-disrupting agents called auristatins, including monomethyl auristatins E and F (MMAE and MMAF). In preclinical models, these auristatins are 100- to 1,000-fold more potent than traditional chemotherapy drugs.

**PBDs**

We have developed another proprietary ADC technology that uses a highly potent DNA binding agent called a pyrrolobenzodiazepine (PBD) dimer. The targeted antibody is attached to the PBD with our proprietary site-specific conjugation technology with engineered cysteines (EC-mAb). PBD dimers are significantly more potent than systemic chemotherapeutic drugs and the site-specific conjugation technology allows two uniform attachment sites of the cell-killing PBD agent to the antibody.

**ADCs: An Integral Part of Cancer Therapy**

By targeting specific tumor-associated receptors on the surface of cancer cells, ADCs have the potential to spare non-targeted cells and reduce toxic side effects. Other approaches to cancer treatment target pathways inside the cell or activate immune cells. Various combinations of these novel modalities are likely to be the future of treatment in oncology. In addition to advancing our ADC research, we are applying our expertise in targets and antibodies to the area of immuno-oncology. We are conducting clinical trials of ADCETRIS in combination with nivolumab, a checkpoint inhibitor, as part of a collaboration with Bristol-Myers Squibb. We also have a collaboration and license agreement with Unum Therapeutics to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies. We are also conducting clinical trials with SEA-CD40, a novel immuno-oncology agent using our sugar-engineered antibody technology, and SGN-2FF, an oral small molecule.

**Extending Our Opportunities through ADC Technology Collaborations**

Collaborating with other leading biotechnology and pharmaceutical companies is a strategy that generates financial benefit for Seattle Genetics. It extends the reach of our technology into programs being developed by our collaborators, and in some cases, provides us with future pipeline opportunities through co-development or opt-in rights to new ADC product candidates.

Multiple licensing agreements for our proprietary ADC technology have generated more than $350 million to date and the potential for several billion in future milestone payments based on advancement of collaborator ADCs plus royalties.

Find more details on our ADC technology collaborator program at www.SeattleGenetics.com.
# Deep Oncology Pipeline

## Brentuximab Vedotin

<table>
<thead>
<tr>
<th><strong>HODGKIN LYMPHOMA (HL)</strong></th>
<th><strong>NON-HODGKIN LYMPHOMA (NHL)</strong></th>
<th><strong>Other Programs</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ECHELON-1:</strong> Frontline HL</td>
<td><strong>ALCANZA:</strong> Relapsed CD30-expressing cutaneous T-cell lymphoma</td>
<td><strong>LEUKEMIA &amp; MYELODYSPLASTIC SYNDROME (MDS)</strong></td>
</tr>
<tr>
<td>Frontline HL in patients 60+ (+ nivolumab)</td>
<td><strong>ECHELON-2:</strong> Frontline CD30-expressing mature T-cell lymphoma</td>
<td>Vadastuximab talirine (SGN-CD33A)</td>
</tr>
<tr>
<td>Second-line HL (+ nivolumab)</td>
<td><strong>Relapsed CD30-expressing diffuse large B-cell lymphoma (DLBCL)</strong></td>
<td>CASCADE: Frontline acute myeloid leukemia (AML)</td>
</tr>
<tr>
<td></td>
<td>Relapsed NHL (+ nivolumab)</td>
<td>Frontline MDS</td>
</tr>
</tbody>
</table>

**Phase 3: Enrollment Complete**

**Phase 2: Enrolling**

**Phase 2: Enrolling**

**Phase 3: Full data reported**

**Phase 2: Enrolling**

**Phase 2: Enrolling**

**Phase 1/2: Enrolling**

### LEUKEMIA & MYELODYSPLASTIC SYNDROME (MDS)

Vadastuximab talirine (SGN-CD33A)

- **CASCADE:** Frontline acute myeloid leukemia (AML)
- Frontline MDS
- Frontline younger AML

**Phase 3: Enrolling**

**Phase 1/2: Enrolling**

**Phase 1: Enrolling**

### SOLID TUMORS

**Enfortumab vedotin** (ASG-22ME)

- Metastatic urothelial cancer

**SGN-LIV1A**

- Metastatic breast cancer

**ASG-15ME**

- Metastatic urothelial cancer

**Phase 1: Enrolling**

**Phase 1: Enrolling**

**Phase 1: Enrolling**

### NHL

Denintuzumab mafodotin (SGN-CD19A)

- Frontline and relapsed DLBCL

**SGN-CD19B**

- Relapsed aggressive B-cell NHL

**Phase 2: Enrolling**

**Phase 1: Enrolling**

### MULTIPLE MYELOMA

**SGN-CD352A**

- Relapsed multiple myeloma

**SGN-CD48A**

- Relapsed multiple myeloma

**Preclinical**

### IMMUNO-ONCOLOGY

SEA-CD40

- Advanced hematologic malignancies and solid tumors

**Phase 1: Enrolling**

**Phase 1: Enrolling**

**Phase 1: Enrolling**

* Program being developed in collaboration with Astellas
Recent Corporate Highlights

- April 2017: Highlighted our leadership in antibody-drug conjugate technology innovation and novel immuno-oncology programs at the American Association for Cancer Research (AACR) Annual Meeting with 14 presentations, including four orals.
- February 2017: Announced global license agreement with Immunomedics for sacituzumab govitecan (IMMU-132).
- January 2017: Enrolled first patient in phase 1 trial of our ninth clinical-stage program, SGN-CD352A, an ADC for multiple myeloma.
- December 2016: Presentations at the 58th American Society of Hematology (ASH) Annual Meeting highlighted our expanding global leadership in the development of innovative antibody-drug conjugates; 18 abstracts accepted, and eight oral presentations, including full results of the phase 3 ALCANZA trial of ADCETRIS® (brentuximab vedotin) in cutaneous T-cell lymphoma and four oral presentations featuring data from clinical studies exploring vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia.
- November 2016: Received FDA Breakthrough Therapy Designation for ADCETRIS in mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.

SGEN Quick Facts

- NASDAQ SYMBOL: SGEN
- CASH AND INVESTMENTS: $619 million as of December 31, 2016
- COMMON STOCK OUTSTANDING: Approximately 140 million shares
- FISCAL YEAR END: December 31
- YEAR FUNDED: 1998
- GLOBAL HEADQUARTERS: Bothell, WA USA
- EUROPEAN HEADQUARTERS: Zug, Switzerland
- INVESTORS: Peggy Pinkston, 425.527.4160 Investors@seagen.com
- MEDIA: Brandi Robinson, 425.527.2910 Media@seagen.com
- TECHNOLOGY LICENSING: BusinessDevelopment@seagen.com
- GENERAL INQUIRIES: Contact@seagen.com
- FOLLOW US ON TWITTER: @SeattleGenetics

Senior Management Team

Clay B. Siegall, Ph.D.
PRESIDENT & CHIEF EXECUTIVE OFFICER

Eric L. Dobmeier
CHIEF OPERATING OFFICER

Jonathan Drachman, M.D.
CHIEF MEDICAL OFFICER AND EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT

Vaughn B. Himes, Ph.D.
CHIEF TECHNOLOGICAL OFFICER

Todd E. Simpson
CHIEF FINANCIAL OFFICER

Darren Cline
EXECUTIVE VICE PRESIDENT, COMMERCIAL

Jean L. Liu, J.D.
GENERAL COUNSEL, EXECUTIVE VICE PRESIDENT, LEGAL AFFAIRS

Christopher Pawlowicz
EXECUTIVE VICE PRESIDENT, HUMAN RESOURCES

Elaine Waller, Pharm.D.
EXECUTIVE VICE PRESIDENT, REGULATORY AFFAIRS

Board of Directors

Clay B. Siegall, Ph.D.
PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF DIRECTORS, SEATTLE GENETICS, INC.

Srinivas Akkaraju, M.D., Ph.D.
FOUNDER AND MANAGING GENERAL PARTNER AT SAMSARA BIOCAPITAL

Felix J. Baker, Ph.D.
CO-MANAGING MEMBER OF BAKER BROS. ADVISORS

David W. Gryska
EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, INCYTE CORPORATION

Marc E. Lippman, M.D.
KATHLEEN AND STANLEY GLASER PROFESSOR AND DEPUTY DIRECTOR, SYLVESTER COMPREHENSIVE CANCER CENTER, UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE

John A. Orwin
CHIEF EXECUTIVE OFFICER, RELYPSA, INC.

Nancy A. Simonian, M.D.
CHIEF EXECUTIVE OFFICER, SYROS PHARMACEUTICALS, INC.

Daniel G. Welch
EXECUTIVE PARTNER, SOFINNOVA VENTURES

Seattle Genetics, ADCETRIS and the ADCETRIS logo are US registered trademarks of Seattle Genetics, Inc. Other trademarks are property of their respective owners. Certain of the statements made in this fact sheet and elsewhere are forward looking. These statements are based on factors that involve risks and uncertainties, and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties associated with fulfilling sales, marketing and distribution requirements; the acceptance of ADCETRIS in the marketplace; the status of reimbursement from third-party payors; risks inherent in clinical stage development and risks that our collaborators do not fulfill their obligations. For additional information on these and other factors that could affect Seattle Genetics’ results, see the reports filed by the company with the SEC, which are available at www.sec.gov. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.